Miranda Felty
Medical · Harrisburg, PANPI 1265871545
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 929 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 27.7% of the total. 2025 is the largest year on record at $4,566, 2.9 times the $1,562 reported in 2021. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 929 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Ardelyx, Inc.$564
- Madrigal Pharmaceuticals$561
- plus $4K from 31 others
What the payments were for
- Food & beverage$13,89999%
- Education$1701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 228 | $3,901 |
| Johnson & Johnson | 176 | $2,299 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 105 | $1,345 |
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $1,132 |
| Ardelyx, Inc. | 36 | $564 |
| Madrigal Pharmaceuticals | 16 | $561 |
| Regeneron Healthcare Solutions, Inc. | 32 | $525 |
| Bristol Myers Squibb | 34 | $499 |
| Pfizer | 25 | $423 |
| QOL Medical, LLC | 22 | $374 |
| Lilly USA, LLC | 22 | $305 |
| Celltrion USA Inc. | 15 | $237 |
| Phathom Pharmaceuticals, Inc. | 42 | $225 |
| Merck | 12 | $204 |
| Novo Nordisk | 7 | $197 |
| Sanofi | 11 | $183 |
| Ipsen Biopharmaceuticals, Inc | 9 | $141 |
| Gilead | 18 | $131 |
| Intercept Pharmaceuticals, Inc. | 8 | $131 |
| Ironwood Pharmaceuticals, Inc | 6 | $89 |
| E.r. Squibb & Sons, L.L.C. | 2 | $85 |
| Daiichi Sankyo Inc. | 4 | $80 |
| Ferring Pharmaceuticals Inc. | 5 | $62 |
| Nestle Healthcare Nutrition Inc. | 4 | $52 |
| Organon | 2 | $43 |
| Amgen | 2 | $41 |
| Exact Sciences | 2 | $37 |
| Redhill Biopharma Inc. | 2 | $30 |
| Aimmune Therapeutics, Inc. | 2 | $27 |
| Evoke Pharma, Inc. | 2 | $27 |
| Braintree Laboratories, Inc. | 2 | $26 |
| Boehringer Ingelheim | 1 | $18 |
| Intra-sana Laboratories | 1 | $16 |
| Micro-tech Endoscopy USA, Inc. | 1 | $16 |
| Orphalan Inc | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,069 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 46 | $195,958 |
| LinzessLinaclotide | 162 | $119,712 |
| XifaxanRifaximin | 29 | $74,353 |
| RelistorMethylnaltrexone Bromide | 16 | $38,294 |
| MovantikNaloxegol Oxalate | 67 | $36,729 |
| IbsrelaTenapanor Hcl | 14 | $34,797 |
| ViberziEluxadoline | 24 | $34,783 |
| Mesalamine | 34 | $16,720 |
| Dexlansoprazole DrDexlansoprazole | 46 | $15,390 |
| TrulancePlecanatide | 19 | $13,780 |
| Lubiprostone | 55 | $9,484 |
| Pantoprazole Sodium | 390 | $6,058 |
| MotegrityPrucalopride Succinate | 12 | $6,013 |
| Dicyclomine Hcl | 292 | $5,878 |
| Famotidine | 333 | $5,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Viberzi | $3,901 | $350,453232 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance | $1,345 | $126,42764 claims |
| Redhill Biopharma Inc.Movantik | $30 | $36,72967 claims |
| Ardelyx, Inc.Ibsrela | $564 | $34,79714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,132 | $6,01312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Harrisburg
- Jacqueline KernaghanSpringfield$426K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.